Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
For quite a while now, the perception of the STEM
The Nobel Prize in Physiology or Medicine awarded
Shilpa Medicare – the full-service contract de
Alembic Pharmaceuticals Limited (Alembic) today an
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
Pharma major Dr Reddy’s Laboratories Ltd has propelled Invista. It is a detailing of Dasatinib that is bioequivalent to the pioneer brand.
Patent on Dasatinib is possessed by Bristol-Myers-Squibb. The Indian patent has lapsed on April 12, 2020.
It is demonstrated for the treatment of ceaseless quickened or myeloid or lymphoid impact stage and recently analyzed in interminable stage grown-up patients with Chronic Myeloid Leukemia (CML) in India.
“The improvement and dispatch of Invista is a critical advance forward in improving access to drugs at a reasonable cost for CML patients in India,” M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories said in a discharge on Monday.
Hyderabad – based Dr Reddy’s Invista is accessible in qualities of 50, 70 and 100 mg
